Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

4.2M FreeStyle Libre glucose monitors recalled by FDA for risk of overheating, fire The issue affects more than 4.2 million devices across the US, the FDA says.

Since Freestyle Libre 1 only came to the US last fall and still lacks some of the functionality of the European version (notably, it can be read by only a special reader, not a smartphone), it’s ...

Pharma giant Abbott said today it had received approval from the FDA for its next-generation glucose monitoring system for ages four and older with diabetes. The FreeStyle Libre 2 iCGM has a 14 ...

On Monday, J.P. Morgan and Morgan Stanley reiterated their Overweight ratings on Abbott Laboratories (ABT). The company’s newest continuous glucose monitor (CGM), the Freestyle Libre 3, recently ...

These studies both investigated the use of FreeStyle Libre for 14 days, and so only short-term outcomes were reported. The Edge et al. study included people aged 4 to 17 years so the outcomes are ...

When the FreeStyle Libre is up and running, however, its true pleasures—a word one rarely attaches to diabetes technology—are clear. Pressing a large physical button on the device primes it to ...

In Q1 2024, Abbott's FreeStyle Libre sales grew 25.5% to reach $1.5bn. The Plus version is gradually replacing the older FreeStyle Libre 2 sensor across many markets.

The company’s FreeStyle Libre continuous glucose monitors raked in $1.1 billion for the quarter—helped along by sales growth of more than 40% in the U.S., according to the earnings report.